Host: Martin J. Abrahamson, MD, FACP, FRCP

Guest: Stefano Del Prato, MD

Guest: Linong Ji, MD

On-demand webcast with expert faculty presentation highlighting key studies in diabetes from the 2025 American Diabetes Association and European Association for the Study of Diabetes annual meetings.

Faculty: Iacopo Olivotto, MD

Faculty: Ahmad Masri, MD, MS

Faculty: Pablo Garcia-Pavia, MD, PhD

Faculty: Fabian Knebel, MD, PhD

Faculty: Caroline Coats, MD

Hypertrophic cardiomyopathy (HCM) management is being transformed by advances in diagnostics and the emergence of targeted therapies. In this program, leading international experts review challenges in early recognition, the evolving role of beta-blockers and traditional therapies, and the clinical impact of novel cardiac myosin inhibitors. Data from pivotal studies—including the landmark MAPLE-HCM trial—are examined in depth, with a focus on exercise capacity, gradient reduction, biomarkers, and patient outcomes. Faculty also share practical strategies for patient selection, monitoring, and translating trial evidence into daily cardiology practice.

Faculty: Brooks D. Cash, MD, AGAF, FACG, FACP, FASGE

Faculty: Kimberly D. Orleck, PA-C

Presented at the 21st Annual Women’s Health Annual Visit (WHAV 2025), this session reviews strategies for diagnosing and treating irritable bowel syndrome (IBS), with a focus on distinguishing IBS-C from IBS-D. Faculty explore the burden of disease, stigma, and the importance of a positive diagnostic strategy using Rome IV criteria, supported by history, physical examination, and selective testing. Treatment approaches include lifestyle changes, pharmacologic interventions, and brain-gut behavioral therapies.

Faculty: Alison Kole

Faculty: Ghada Bourjeily, MD, FCCP

Faculty: Rashmi Nisha Aurora, MD

Faculty: Audrey Wells, MD

This WHAV 2025 session addresses obstructive sleep apnea (OSA) in women, highlighting how phenotype and risk factors shift across life stages. Experts discuss how varying phenotypes contribute to delayed diagnosis and review screening tools, referral strategies, evidence linking OSA to cardiometabolic risks in menopause and pregnancy and available treatment options. The program underscores the importance of a precision medicine approach informed by phenotype, hormonal status, and patient goals at each stage of a woman’s life.

Host: An De Vriese, MD, PhD

Faculty: Muh Geot Wong, MBBS, PhD

Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline application, highlighting the use of sparsentan in a patient with persistent proteinuria despite RAASi therapy. The faculty also explore combination treatment approaches, including SGLT2 inhibitors, and reference data from the SPARTAN and SPARTACUS studies.

Host: Andrew F. Alexis, MD, MPH

Guest: Daniel C. Butler, MD

Guest: Shawn G. Kwatra, MD

Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.

Faculty: Milind Y. Desai, MD, MBA

Faculty: Iacopo Olivotto, MD

Faculty: Elena Arbelo, MD, PhD

This expert-led program delves into the evolving clinical management of obstructive hypertrophic cardiomyopathy (HCM), emphasizing real-world decision-making across diverse patient profiles. Through dynamic case studies—from young patients with unexplained syncope to older adults at a procedural crossroads—faculty explore how to tailor care using guideline-driven tools and therapeutic advances. Special attention is given to the role of the cardiac myosin inhibitor mavacamten, with discussion of long-term data, safety considerations, and its integration into personalized treatment plans.

Faculty: Prof. Ulrich Laufs

Faculty: Pam R. Taub, MD, FACC, FASPC

Faculty: Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma

Faculty: Christie Ballantyne, MD

Cardiologists explore advances in lipid management, from statin intolerance to emerging lipid targets like ApoB and non-HDL cholesterol. The series emphasizes the pivotal role of combination therapy—including ezetimibe, PCSK9 inhibitors, and novel agents such as bempedoic acid and inclisiran—in achieving LDL-C goals. Special focus is given to cholesteryl ester transfer protein (CETP) inhibition as a breakthrough strategy, with trials showing potent LDL-C reduction, improved goal attainment, and promising effects on cognition and inflammation. Together, these discussions highlight how CETP inhibitors may redefine future cardiovascular therapy.

Faculty: John McMurray, MD

Faculty: Scott Solomon, MD

Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks.

Faculty: James M. Cleary, MD, PhD

This activity examines first-line treatment strategies for advanced HER2-negative upper gastrointestinal cancers. Expert commentary highlights the role of biomarker testing, including PD-L1 CPS and CLDN18.2, in guiding therapeutic decisions. Key clinical trial data on anti-PD-1 therapies such as nivolumab, pembrolizumab, and tislelizumab are discussed, along with regimen-specific adverse event profiles. Patient case examples illustrate the application of guideline-based treatment selection utilizing biomarker status in clinical practice.